Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models

Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalidomide (POM) is a novel immunomodulatory drug with anti-lymphoma activity. CNS pharmacokinetic analysis was performed in rats to assess the CNS penetration of POM. Preclinical evaluation of POM was per...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhimin, Qiu, Yushi, Personett, David, Huang, Peng, Edenfield, Brandy, Katz, Jason, Babusis, Darius, Tang, Yang, Shirely, Michael A., Moghaddam, Mehran F., Copland, John A., Tun, Han W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734315/
https://www.ncbi.nlm.nih.gov/pubmed/23940785
http://dx.doi.org/10.1371/journal.pone.0071754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734315/
https://www.ncbi.nlm.nih.gov/pubmed/23940785
http://dx.doi.org/10.1371/journal.pone.0071754

Ejemplares similares